In adult patients, the phase I OPARATIC study in recurrent GBM demonstrated that the PARP inhibitor, olaparib, penetrated to tumor in of 100% of patients on study and identified a safe dosing strategy for intermittent olaparib dosing in combination with continuous TMZ to overcome overlapping hematologic toxicity (56). The gene discussed is PARP1; the disease is neoplasm.